PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Alcami Announces Promotion of Robert Tragas to Vice President, Laboratory Services

Alcami, a leading contract development and manufacturing organisation (CDMO), today announced its strengthening of laboratory leadership with the promotion of Robert Tragas to Vice President, Laboratory Services.

In his expanded role, Mr. Tragas will lead laboratory operations across Alcami’s Research Triangle Park campus, overseeing analytical, biologics, microbiology and environmental monitoring functions. His leadership will focus on driving alignment, operational excellence and continued growth across the laboratory organisation.

Mr. Tragas joined Alcami more than 26 years ago and has held roles of increasing responsibility throughout the organisation. Known for his technical expertise, operational leadership and ability to execute complex scientific programmes, he has played a central role in expanding Alcami’s analytical and biologics capabilities. As demand for biologics continues to grow, his leadership will be essential in scaling capabilities and supporting the next phase of growth.

“By strengthening our laboratory leadership, we are positioning Alcami to serve as an even stronger partner for sponsors developing the next generation of biologic medicines,” said Katie Schlipp, President Laboratory Services at Alcami.

With the promotion of Mr. Tragas, Alcami continues to build a robust leadership foundation to support clients advancing specialised therapies from development through delivery to patients.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC